Koers Nymox Pharmaceutical Corporation
Aandelen
NYMXF
BSP733981026
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,29 USD | +7,41% | -20,13% | -50,85% |
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 29,51 mln. 27,71 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -12 mln. -11,27 mln. | Nettowinst (verlies) 2022 | -6 mln. -5,64 mln. | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 439K 412K | Nettoliquiditeiten 2022 | 1,23 mln. 1,16 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-8,5
x | K/w-verhouding 2022 |
-4,39
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 57,95% |
1 dag | +7,41% | ||
1 week | -20,13% | ||
Lopende maand | -27,50% | ||
1 maand | -16,18% | ||
3 maanden | -34,09% | ||
6 maanden | -58,57% | ||
Lopend jaar | -50,85% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 30-05-95 |
Patrick Doody
BRD | Director/Board Member | - | 12-07-23 |
Director/Board Member | - | 21-03-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 08-06-06 |
Paul Averback
CEO | Chief Executive Officer | 73 | 30-05-95 |
Director/Board Member | 88 | 01-07-15 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
18-04-24 | 0,29 | +7,41% | 10 614 |
17-04-24 | 0,27 | -10,00% | 92 604 |
16-04-24 | 0,3 | -17,37% | 19 541 |
15-04-24 | 0,3631 | 0,00% | 556 |
11-04-24 | 0,3631 | -6,90% | 13 682 |
uitgestelde koers OTC Markets, 18 april 2024 om 18:09 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-50,85% | 25,21 mln. | |
-1,92% | 41,36 mld. | |
+44,25% | 41,3 mld. | |
+3,08% | 39,61 mld. | |
-12,11% | 25,62 mld. | |
+3,38% | 24,09 mld. | |
-24,28% | 18,38 mld. | |
+23,47% | 11,85 mld. | |
-3,38% | 11,82 mld. | |
+7,93% | 11,07 mld. |